Biotech

All Articles

Regeneron's Opdualag opponent reveals 57% action rate

.Regeneron is actually back with lasting follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo ...

AstraZeneca blog posts information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early check out the efficiency of its own internal antibody-drug conj...

iTeos- GSK's TIGIT superstar presents significant renovation

.After announcing a period 3 launch based upon good midstage end results, iTeos as well as GSK are e...

More collaborative FDA can accelerate unusual illness R&ampD: report

.The FDA should be actually much more open and also collective to unleash a rise in commendations of...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapies...

Atea's COVID antiviral stops working to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually neglected an additional COVID-19 test, yet the biotech...

Neurocrine's proposal to conserve schizophrenia possibility stops working

.Neurocrine Biosciences' schizophrenia plan pivot has actually fallen short. The biotech was incapab...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has made a late entry to the radioligand party, paying out 100 million euros ($ 110 thousand...

F 2G rears $100M for second effort to get brand new antifungal to market

.After F2G's first effort to obtain a brand-new class of antifungal to market was wrecked by the FDA...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 systems amidst profitability stress

.Moderna has sworn to cut R&ampD investing through $1.1 billion by 2027. The selection to retract th...